Reducing The Risk Of Heart Failure | Boehringer Ingelheim IN

These breakthrough results demonstrate the potential of Empagliflozin to positively impact the lives of adult patients across the entire spectrum of heart failure.
‘Heart failure with preserved ejection fraction’ represents a large unmet need in cardiac care, which is predisposed by common disorders like hypertension, anemia, diabetes, kidney disease, or old-age, and so far, does not have any approved treatment option beyond the control of risk-factors and symptoms.
With approval, Empagliflozin would become the first and only clinically proven therapy to improve outcomes for the full spectrum of heart failure patients, regardless of ejection fraction.
Empagliflozin - the first SGLT2-inhibitor therapy to prove reduction in risk of cardiovascular death, in people with type 2 diabetes and established cardiovascular disease, is now evidenced for heart failure with preserved as well as reduced ejection fraction.

India, 01 September 2021 – The breakthrough results of EMPEROR-Preserved trial reveal that Empagliflozin reduces the combined relative risk of cardiovascular death or hospitalization for heart failure by 21%, in adult patients who suffer from heart failure with preserved ejection fraction (HFpEF), with or without diabetes. The trial investigated empagliflozin (10 mg) versus placebo. The results were presented at the ESC Congress 2021, the annual meeting of the European Society of Cardiology. The EMPEROR heart failure studies are part of Boehringer Ingelheim’s EMPOWER clinical trial program exploring the effect of empagliflozin across a spectrum of cardio-renal-metabolic diseases.

Heart failure with preserved ejection fraction occurs when the left ventricle of the heart is unable to fill properly, resulting in less blood being pumped to the body. Heart failure poses a significant global disease burden, more than 60 million patients worldwide have heart failure and half of them have Heart Failure with Preserved Ejection Fraction. For this condition, there has been no prior treatment, which has the potential to modify the underlying disease. The treatment consists of controlling risk-factors like blood pressure, kidney disease, anemia, and diabetes. In terms of modifying the underlying disease, the EMPEROR-Preserved trial results provide the first conclusive evidence.

In India, about 1% to 1.5% of the adult population is estimated to have heart failure. As per the INTER-CHF study, the death-rate within 1-year of a heart-failure event, is higher in India than the global average, and is next only to Africa. The Trivandrum Heart Failure Registry suggested that nearly 2 in 5 Indian patients with Heart Failure with Preserved Ejection Fraction, die within 3 years of their first hospital admission. Further, some key predisposing factors for heart failure with preserved ejection fraction, including hypertension, anemia, obesity, diabetes, and kidney disease, are considerably prevalent in our Indian population.

Dr. Shraddha Bhure, M.D., Medical Director of Boehringer Ingelheim India said, “Heart Failure with Preserved Ejection Fraction is an outcome of heterogeneous diseases and complex underlying problems. It represents about 1/3^rd of all heart failure cases diagnosed in India, whereas globally it represents nearly half of the heart-failure cases. This disparity in the Indian population is likely due to several possibilities, including relatively younger average age of our population, lower likelihood of health-assessment in female patients who are more predisposed to this disease, and lesser awareness about the disease and its care at multiple levels. The results of the EMPEROR-Preserved Phase III trial, which also included a fair patient-representation from India, offers a new hope for patients with Heart Failure with Preserved Ejection Fraction, which so far has been a very difficult entity to treat effectively.”

The EMPEROR-Preserved trial results add to the previous findings from the EMPEROR-Reduced Phase III trial, which showed that Empagliflozin significantly reduced the combined relative risk of cardiovascular death or hospitalization for heart failure by 25 percent, compared to placebo, in adult patients with heart failure with reduced ejection fraction (HFrEF), with or without diabetes.

About Boehringer Ingelheim

Boehringer Ingelheim is working on breakthrough therapies that improve the lives of humans and animals. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. Around 52,000 employees serve more than 130 markets in the three business areas, Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. Learn more at www.boehringer-ingelheim.com

Established in 2003, Boehringer Ingelheim India, manages the India and the neighboring markets operations of the global enterprise. The Company enables access to innovator products as part of its Human Pharma and Animal Health businesses. The focus Human Pharma therapy areas include diabetes, cardiovascular and respiratory conditions. www.boehringer-ingelheim.in

For further information, please contact –
Magline Rufina FR
Director – Communications, Boehringer Ingelheim India
Email: magline.rufina_f_r@boehringer-ingelheim.com

Shivani Srinivas
Archetype
E-mail: shivani.srinivas@archetype.co
Mob: +91 7208056250